Funding for this research was provided by:
Ministry of Research and Technology (AP05130238, Priority area: 439 «Life Science» «Development of biomedicine and genetic engineering)
Agence Nationale de la Recherche et de la Technologie (2015-1177)
Centre Nationale de la Recherche Scientifique
Text and Data Mining valid from 2019-06-24
Received: 18 October 2018
Accepted: 18 June 2019
First Online: 24 June 2019
Ethics approval and consent to participate
: Public health action taken as a result of notification and surveillance is one of the Public Health National Centre for Tuberculosis of Kazakhstan key roles as stated by the Ministry of Health Act and subsequent Government directives which provide a mandate and legislative basis to undertake necessary follow-up. Part of this follow-up is identification of epidemiological and molecular links between cases, helped by the National Center for Biotechnology that provides expertise and links to the Ministry of Research. This study is part of service development carried out under this framework, and as such explicit ethical approval was not mandatory. Moreover, patient data are not traceable by any other third part than by the National Centre for Tuberculosis.
: All authors approved the final version of this submission and provided consent for publication.
: CS and GR were among the founders and shareholders of Beamedex®, at start of the study. They declare not to hold any share in Luminex Corp. (Austin, TX) nor in Luminex B.V. (Hertogenbosch, The Netherlands), that no relative or parents hold any share either in any of these companies, and that they did not receive any salary or financial counterpart from Beamedex® or Luminex Corp. or Luminex B.V. and that they currently do not hold any Beamedex® share.